On August 2, 2024 the U.S. Food and Drug Administration (FDA) approved afamitresgene autoleucel (afami-cel, Tecelra), a breakthrough cellular therapy for treating metastatic synovial sarcoma, a rare and aggressive type of soft tissue cancer. This approval represents a significant milestone, introducing the first T-cell receptor (TCR) therapy for cancer.
What is Afami-cel?
Afami-cel leverages a patient’s own T cells—an essential component of the immune system. These cells are extracted from the patient’s blood, genetically modified in a laboratory to enhance their ability to target cancer cells, and then infused back into the patient. This genetic engineering produces a specialized T-cell receptor capable of recognizing and binding to MAGE-A4, a protein commonly found in synovial sarcoma and other tumors.
Afami-cel is approved for patients with metastatic synovial sarcoma who have undergone prior chemotherapy, and whose tumors test positive for the presence of MAGE-A4 and certain types of HLA proteins.
Clinical Trial Results
The FDA’s decision was based on a pivotal clinical trial involving 44 participants with metastatic synovial sarcoma. Results showed that the therapy shrank tumors in 43% of patients, with a median response duration of six months. Two participants experienced complete responses, meaning their tumors disappeared and did not return during the three-year study period.
“This is a landmark advancement for patients with metastatic synovial sarcoma,” said Dr. Sandra D’Angelo of Memorial Sloan Kettering Cancer Center, who led the trial. She emphasized that afami-cel sets a new standard of care for eligible patients.
T-Cell Receptor Therapy vs. CAR T-Cell Therapy
Afami-cel belongs to a new class of therapies distinct from CAR T-cell therapies. This have been effective in treating certain blood cancers. CAR T-cell therapies use synthetic receptors to target surface proteins, while afami-cel uses modified natural receptors to target proteins inside cancer cells. These internal proteins are displayed on the cell surface by HLA proteins. This allows the immune system to recognize and attack cancer cells.
Addressing the Urgent Need for Synovial Sarcoma Treatments
Synovial sarcoma, which develops in connective tissues such as muscles or ligaments, is extremely rare, with fewer than 1,000 new cases annually in the U.S. About one-third of cases occur in individuals under 30 years old.
For patients with localized disease, treatment typically involves surgical removal of the tumor, often supplemented by radiation or chemotherapy. However, approximately 50% of patients develop metastatic disease, which has historically been incurable and treated primarily with chemotherapy.
Dr. D’Angelo highlighted the critical need for innovative therapies, as it has been over a decade since a new treatment was approved for synovial sarcoma.
How Afami-cel Works
Doctors manufacture afami-cel over a six-week period. During this time, they genetically engineer the patient’s T cells to express a receptor that can tightly bind to MAGE-A4. This tight binding ensures the immune cells can effectively recognize and destroy cancer cells.
Unlike CAR T-cell therapies, which focus on surface proteins, T-cell receptor therapies can target proteins inside cancer cells. Afami-cel’s ability to target MAGE-A4 expands and its potential use to other cancers, such as ovarian and head and neck cancers.
Managing Challenges During Treatment
Administering afami-cel involves several steps:
- Lymphodepletion Therapy: Patients receive high-dose chemotherapy to create space in the bone marrow for the engineered T cells. This process, while effective, can cause side effects such as low white blood cell counts.
- Bridging Therapy: During the six-week manufacturing period, some patients may require additional treatments, such as chemotherapy, to control tumor growth. In the clinical trial, 40% of participants received bridging therapy.
Safety and Side Effects
The most common side effects of afami-cel include nausea, fatigue, vomiting, and infections. Approximately 70% of patients experienced cytokine release syndrome (CRS). This immune system overreaction was generally mild and manageable with standard treatments.
Dr. David Hong from MD Anderson Cancer Center emphasized that afami-cel should be administered at specialized cancer centers experienced in cellular therapies. This ensures patients receive proper preparation and monitoring for optimal outcomes.
A Promising Future
Afami-cel represents a monumental step forward in treating metastatic synovial sarcoma and sets a precedent for future TCR therapies. Researchers are optimistic about its potential to address other MAGE-A4-expressing cancers, paving the way for broader applications of this innovative technology.
With the FDA’s accelerated approval, afami-cel offers hope. It provides a new treatment option for patients who previously faced limited choices for this challenging disease.
Resource: Learn about afamitresgene autoleucel (afami-cel), the first FDA-approved T-cell therapy for metastatic synovial sarcoma. Discover how this breakthrough treatment works, clinical trial results, and its potential to revolutionize cancer care.
